TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27359067
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (4000 IU daily) for 2 months prior to surgery
Study: 23895860
Drug: Dexmedetomidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.3 µg/kg loading dose, 0.3 µg·kg(‐1)·h(‐1) maintenance dose)
Study: 22180397
Drug: Dose-dense weekly
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose-dense weekly paclitaxel 80 mg/m(2) plus 3-weekly carboplatin AUC 6
Study: 22180397
Drug: 3-weekly paclitaxel/carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-weekly paclitaxel/carboplatin
Study: 17116705
Drug: Chili (4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chili (4.2 g dry powder, 25 mg polyphenols as gallic acid equivalents)
Study: 17116705
Drug: Turmeric (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric (0.5 g dry powder, 50 mg polyphenols as gallic acid equivalents)
Study: 17116705
Drug: Chili (4.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chili (4.2 g dry powder)
Study: 14742340
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% solution (0.7 ml x kg(‐1))
Study: 14742340
Drug: Ropivacaine 0.375%
Normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.375% solution (0.7 ml x kg(‐1))
Study: 10188789
Drug: WAL 2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAL 2014 (40 mg and higher)
Study: 10188789
Drug: WAL 2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAL 2014 (80 mg)
Study: 10188789
Drug: WAL 2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAL 2014 (120 mg and 160 mg)
Study: 10188789
Drug: WAL 2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAL 2014 (100 mg-140 mg)
Study: 10188789
Drug: WAL 2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAL 2014 (100 mg upwards)
Study: 10188789
Drug: WAL 2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAL 2014 (40, 60, 80, 100, and 140 mg)
Study: 653534
Drug: Pyridoxine administration
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine administration in normal postpartum women
Study: 653534
Drug: Pyridoxine administration
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine administration in patients with chlorpromazine-induced hyperprolactinaemia
Study: 26159452
Drug: Tweeting arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tweeting arm (intervention group) - three tweets daily using Hootsuite with specific content related to the systematic reviews.
Study: 22001341
Drug: Vibration-assisted anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration-assisted anesthesia during BTX‐A injections
Study: 22001341
Drug: BTX‐A injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTX‐A injections alone (control)
Study: 19441605
Drug: loratadine-montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine-montelukast (10 mg/10 mg)
Study: 19441605
Drug: phenylephrine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylephrine (10 mg)
Study: 8993254
Drug: Methylprednisolone 20
Normalized name: methylprednisolone 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 20 mg/kg body weight (S group)
Study: 25375979
Drug: TNF‐α (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF‐α (12 ng/kg/h) infusion
Study: 22256576
Drug: FA plus
Normalized name: Medorfa Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA plus TH (Flurbiprofen axetil 4 mg kg‐1 . 24 hr‐1 and Tramadol hydrochloride 2 mg kg‐1 . 24 hr‐1 after bolus injection of FA 50 mg)
Study: 22256576
Drug: FA alone
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FA alone (Flurbiprofen axetil 4 mg kg‐1 . 24 hr‐1)
Study: 19565736
Drug: Pricking blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pricking blood therapy combined with ultraviolet irradiation
Study: 19565736
Drug: Aciclovir and
Normalized name: Aciclovir and hydrocortisone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aciclovir and other western medicine
Study: 15830732
Drug: Gradual withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal treatment approaches
Study: 7943451
Drug: mCPP (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: mCPP (0.1 mg/kg)
Study: 8513291
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (200 mg starting dose, followed by 100 mg weekly)
Study: 7118065
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg p.o.)
Study: 2878867
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5 mg sublingually)
Study: 30053278
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg 25(OH)D3 daily
Study: 30053278
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg vitamin D3 daily
Study: 25093275
Drug: 135 g
Normalized name: SODIUM CHLORIDE 0.135 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 g serving of lean beef (tinned meat) providing 20 g of protein and 1.7 g of fat after resistance training.
Study: 21111314
Drug: Ultraviolet-A/riboflavin CXL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultraviolet-A/riboflavin CXL therapy
Study: 18515652
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) for 3 months
Study: 15837100
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of T. arjuna
Study: 24766973
Drug: Rivaroxaban 20
Normalized name: rivaroxaban 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 20 mg once daily (15 mg if creatinine clearance is 30‐49 mL/min)
Study: 24766973
Drug: Dose-adjusted vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted vitamin K antagonists (VKAs; INR 2.0‐3.0)
Study: 24766973
Drug: Rivaroxaban or
Normalized name: rivaroxaban Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban or VKA administered for 21 to 56 days before cardioversion
Study: 24766973
Drug: Rivaroxaban or
Normalized name: rivaroxaban Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban or VKA administered for 6 weeks postcardioversion
Study: 1312002
Drug: Quinapril 20
Normalized name: quinapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 20 mg
Study: 11583728
Drug: Cilostazol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol (100 mg, twice daily)
Study: 11583728
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg, twice daily)
Study: 10741176
Drug: 0.02% mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% mitomycin C solution
Study: 2807523
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR vaccine (5 x 10^8 organisms)
Study: 131976
Drug: Hydrocortisone hemisuccinate
Normalized name: Hydrocortisone Hemisuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone hemisuccinate (steroid group)
Study: 131976
Drug: Non-steroid treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid treatment (control group)
Study: 23336549
Drug: Problem-solving intervention
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving intervention (five weekly 90-minute group sessions)
Study: 21700924
Drug: Hand‐arm intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand‐arm intensive bimanual therapy (HABIT)
Study: 16625986
Drug: Sublingual desmopressin
Normalized name: desmopressin Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual desmopressin 160 microg
Study: 16625986
Drug: Sublingual desmopressin
Normalized name: desmopressin Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual desmopressin 240 microg
Study: 16625986
Drug: Sublingual desmopressin
Normalized name: desmopressin Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual desmopressin 320 microg
Study: 16625986
Drug: Sublingual desmopressin
Normalized name: desmopressin Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual desmopressin (all doses)
Study: 9154395
Drug: 1% Lamisil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Lamisil emulsion gel
Study: 7895384
Drug: Intranasal sodium
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sodium cromoglycate (single dose)
Study: 7895384
Drug: Intranasal sodium
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sodium cromoglycate (3-week course)
Study: 3266156
Drug: Spironolactone (100‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100‐200 mg/day)
Study: 3266156
Drug: Potassium canrenoate
Normalized name: Potassium canrenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate (50‐100 mg/day)
Study: 28708863
Drug: IL-2 administration
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 administration with therapeutic vaccination (ALVACHIV/Lipo-6T)
Study: 22555974
Drug: IL-2 administration
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-2 administration
Study: 23922114
Drug: Panobinostat 40
Normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat 40 mg thrice weekly (initially), then reduced to 20 mg thrice weekly after nine patients due to safety concerns.
Study: 12796155
Drug: Salmeterol, 50
Normalized name: Fluticasone-Salmeterol, 500 mcg-50 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol, 50 micro g bid
Study: 11007224
Drug: Titration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titration of doses every 3 min until predefined levels of somnolence were achieved
Study: 8985524
Drug: Mefloquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (25 mg/kg total, divided into 15 mg/kg initially and 10 mg/kg after 12 hours)
Study: 1476911
Drug: Nifedipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (calcium blocker)
Study: 29187594
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma urate (100 µmol/L increase)
Study: 29187594
Drug: Genetically determined
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically determined high plasma urate (100 µmol/L increase)
Study: 26891879
Drug: Novel glutamate-modulating
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Novel glutamate-modulating agents
Study: 22527829
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (total dose 2160 mg i.v.) + 0.45% saline (1 mL/kg/h over 24 h)
Study: 22527829
Drug: N-acetylcysteine (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (total dose 4800 mg p.o.) + 0.45% saline (1 mL/kg/h over 24 h)
Study: 20484838
Drug: Beverages with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverages with apple polyphenols (600 mg)
Study: 12097660
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (100 mg Fe/d as ferrous sulfate) for 6 weeks
Study: 12097660
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (22 mg Zn/d as zinc gluconate) for 6 weeks
Study: 10081531
Drug: Ketorolac 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.9 mg kg‐1 i.v.
Study: 10081531
Drug: Pethidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.5 mg kg‐1 i.v.
Study: 7593724
Drug: Moclobemide once
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide once daily (OD)
Study: 7593724
Drug: Moclobemide three
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide three times daily (TDS)
Study: 2407336
Drug: IF radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IF radiotherapy + MOPP chemotherapy
Study: 2407336
Drug: IF radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IF radiotherapy + MOPP chemotherapy (CCSG and CALGB)
Study: 30369321
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for OSA diagnosis and treatment
Study: 30369321
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care for OSA diagnosis and treatment
Study: 24909563
Drug: Conservative treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatments (1 or more)
Study: 19461562
Drug: 12.5 mg/mL
Normalized name: cresol 12.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/mL morphine with 0.2% ropivacaine
Study: 19461562
Drug: 25 mg/mL
Normalized name: hemin 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/mL morphine with 0.2% ropivacaine
Study: 17617283
Drug: Moxonidine 0.2
Normalized name: moxonidine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.2 mg once daily (M0.2)
Study: 17617283
Drug: Moxonidine 0.2
Normalized name: moxonidine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.2 mg BID (M0.4)
Study: 17617283
Drug: Moxonidine 0.2
Normalized name: moxonidine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine 0.2 mg plus Irbesartan 150 mg (M0.2+1)
Study: 15165654
Drug: Skills training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skills training intervention (manual plus five weekly group-based sessions)
Study: 12117747
Drug: Dexrazoxane (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexrazoxane (500 mg/m2)
Study: 10088770
Drug: Intraarticular corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular corticosteroids (3.75 mg of cortivazol in 1.5 ml)
Study: 10088770
Drug: Intraarticular placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular placebo (1.5 ml of 0.9% normal saline)
Study: 7491940
Drug: 56 mg
Normalized name: aspirin 856 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56 mg arginine.kg‐1.day‐1 for 6 days
Study: 7491940
Drug: 561 mg
Normalized name: OCTINOXATE 2.1 mg in 30 mL / OCTISALATE 0.9 mg in 30 mL / TITANIUM DIOXIDE 2.561 mg in 30 mL TOPICAL CREAM [CLE CCC Olive Medium Deep]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 561 mg arginine.kg‐1.day‐1 for 6 days
Study: 23365148
Drug: Ayurvedic formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic formulations (SGCG and SGC)
Study: 23365148
Drug: Glucosamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (2 g daily)
Study: 8751544
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 or 175 mg/m2) over 3 hr followed by cisplatin (75 mg/m2)
Study: 1910100
Drug: Immediate postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postoperative nasojejunal feeding with full strength Osmolite solution for 56 hours (n = 16)
Study: 29395424
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of allogeneic MSCs
Study: 25236322
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clindamycin phosphate plus benzoyl peroxide
Study: 16297756
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion with a preset target concentration of 2.5 microg/mL until sedation level 3 was achieved.
Study: 9704200
Drug: Phenylbutazone 10
Normalized name: phenylbutazone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 10 mg/kg intramuscularly
Study: 9704200
Drug: Control injection
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injection (vehicle-containing local anaesthetic)
Study: 8539544
Drug: Sulfamethoxazole-trimethoprim (SMX-TMP)
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Sulfamethoxazole (DB01015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfamethoxazole-trimethoprim (SMX-TMP) 400/80 mg b.i.d.
Study: 8539544
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (AP) 60 mg every 2nd week
Study: 31900813
Drug: Medication providing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication providing a 'cure' with flu-like symptoms
Study: 31900813
Drug: Medication providing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication providing a 'remission' labeled as 'cure' with flu-like symptoms
Study: 31900813
Drug: Medication providing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication providing a 'remission' without labeling as 'cure'
Study: 31687955
Drug: Nitroglycerin (8-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (8-10 μg/kg*min)
Study: 27559692
Drug: E-cigarette administration
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-cigarette administration
Study: 27559692
Drug: Tobacco cigarette
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco cigarette administration
Study: 11943448
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy alone
Study: 17533020
Drug: Atorvastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin, 40 mg/d for 6 weeks
Study: 17533020
Drug: Gemfibrozil, 600
Normalized name: Gemfibrozil, 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil, 600 mg twice daily for 6 weeks
Study: 15576517
Drug: Oxycodone 10
Normalized name: oxycodone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 10 mg with acetaminophen 650 mg
Study: 8306408
Drug: L-AdVP (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AdVP (doxorubicin, vincristine, prednisolone, and L-asparaginase)
Study: 8306408
Drug: L-AdVP
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-AdVP
Study: 2647291
Drug: Human lymphoblastoid
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human lymphoblastoid interferon (IFN) administered i.m. at doses of 1 x 10(6) units/m2, 3 x 10(6) units/m2, and 10 x 10(6) units/m2
Study: 2647291
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of WBH and human lymphoblastoid IFN
Study: 2647291
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with IFN
Study: 52367
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (quintuple drug regimen: mechloretamine, adriamycin, bleomycin, vincristine, and prednisone)
Study: 52367
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (quintuple drug regimen)
Study: 52367
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy followed by involved field irradiation
Study: 29886347
Drug: Nurse-led group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led group treatment based on CBT-I (n=90)
Study: 29886347
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n=75)
Study: 28756415
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (CBT, RTW-I, COMBO)
Study: 14558436
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg manidipine dihydrochloride
Study: 14558436
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg delapril hydrochloride
Study: 14558436
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of 10 mg manidipine and 30 mg delapril
Study: 3880714
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg penicillamine
Study: 3880714
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg penicillamine
Study: 27344823
Drug: He's fire
Approvals — FDA: no, EMA: no, PMDA: no
Description: He's fire needle therapy applied for 8 weeks
Study: 22420830
Drug: 0.06 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg.kg(‐1) rocuronium priming followed by 0.54 mg.kg(‐1) rocuronium
Study: 22420830
Drug: 50 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg.kg(‐1) magnesium sulphate
Study: 22420830
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of magnesium sulphate and rocuronium priming
Study: 22420830
Drug: 0.6 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg.kg(‐1) rocuronium
Study: 17660483
Drug: Oral roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral roflumilast 500 mug, once daily
Study: 17660483
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of roflumilast and budesonide
Study: 9589648
Drug: Miglitol 25
Normalized name: miglitol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 25 mg TID
Study: 9589648
Drug: Miglitol 50
Normalized name: miglitol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 50 mg TID
Study: 9589648
Drug: Glyburide (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (titrated dose)
Study: 7978718
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 1 mg/d